Skip to content

Pain Reduction in Maxillomandibular Surgery Using Maxillary and Mandibular Nerve Blocks

Analgesic Efficacy of Echoguided Maxillary and Mandibular Nerve Blocks in Planned Maxillomandibular Osteotomy Surgery

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05351151
Acronym
ECHOMAX
Enrollment
50
Registered
2022-04-28
Start date
2022-05-23
Completion date
2023-03-29
Last updated
2025-11-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain, Post Operative, Regional Anesthesia

Keywords

Orthognathic surgery, Maxillary-mandibular osteotomy, Double jaw osteotomy, Bimaxillary surgery, Maxillary nerve block, Mandibular nerve block, Regional anesthesia, Nerve blocks

Brief summary

Maxillo-mandibular osteotomy is a painful surgery which requires mostly opioids use. Recent studies on maxillary and mandibular nerve blocks have suggested benefit in maxillo-facial surgery but have been poorly investigated in orthognathic surgery. This study is designed to evaluate analgesic effectiveness, through opioids consumption, of a bilateral double ultra-sound guided nerve blocks (maxillar and mandibular nerve) in maxillo-mandibular osteotomy.

Detailed description

Maxillo-mandibular osteotomy is a frequent but painful procedure in maxillo-facial surgery. It mostly requires opioids use which lead to well known side effects. Regional anesthesia has strongly modified post-surgical rehabilitation of many procedures. Maxillary nerve block has proved its efficiency on opioid consumption reduction in pediatric cleft palet surgery but has been rarely evaluated in orthognathic surgery. Mandibular nerve block has never been investigated in maxillo-mandibular osteotomy as well as benefit of bilateral ultra-sound guided technique to perform these nerve blocks. Consequently, this trial is designed to evaluate analgesic effectiveness of a double ultra-sound guided nerve blocks (maxillar and mandibular nerve) in maxillo-mandibular osteotomy. This monocentric, single-blinded, randomized controled trial is designed with 2 groups of 25 patients receiving either bilateral double ultra-sound guided nerve block (maxillary and mandibular) with ROPIVACAINE 4.75mg/mL either local infiltration of LIDOCAINE 1% at incision sites by surgeon after general anesthesia induction during maxillo-mandibular osteotomy. Per et post-surgery anesthesic protocol and analgesia are standardized for both group. The main outcome corresponds to opioid consumption in MME of the first 24h after surgery. Follow-up occurs at 24h and 48h after end of surgery to assess analgesia, pain and opioid consumption.

Interventions

PROCEDUREbilateral ultra-sound guided maxillary and mandibular nerve blocks

Interventional group will receive bilateral ultra-sound guided maxillary and mandibular nerve block with ROPIVACAINE 4,75 mg/ml.

PROCEDUREInfiltration of Lidocaine 1%

Intervention requiring the infiltration of LIDOCAINE 1% at incision sites by surgeon after general anesthesia induction during maxillo-mandibular osteotomy

Sponsors

University Hospital, Toulouse
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
15 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

* Patients from 15 to 45 years old, * Scheduled for maxillary-mandibular osteotomy, * Registered in French social insurance register, * With informed consent disclosure.

Exclusion criteria

* American Society of Anesthesiologists (ASA) classification ≥ 3 * Innate or acquired hemostasis pathology, * Peripheric neuropathy, * Drug intake for chronic pain, * Infection/scar at needle insertion site, * Associated rhinoplasty surgery, * Allergy to local anesthetics, * Pregnant woman or potentially, * Breastfeeding woman, * Already registered in other clinical trial, * Adults under legal protection of incapable adult, * Cognitive disease impairing using of evaluation tools performed in protocol, * All contraindication of anesthetics drugs used in protocol.

Design outcomes

Primary

MeasureTime frameDescription
The opioid consumption (in Morphine Milligram Equivalents) after the first 24 hours post-surgery.24 hours post-surgeryThe opioid consumption (in Morphine Milligram Equivalents ) after the first 24hours post-surgery.

Secondary

MeasureTime frameDescription
Maximal pain (Numerical Rating Scale) in recovery room, at 24h after surgery.24 hours after surgeryPain assessment by Simple Numerical Scale (ENS from 0 to 10) in the Postoperative Monitoring Room (maximum value) at the 24th postoperative hour
Maximal pain (Numerical Rating Scale) in recovery room, at 48 hours after surgery.48 hours after surgeryPain assessment by Simple Numerical Scale (ENS from 0 to 10) in the Postoperative Monitoring Room (maximum value) at the 48th postoperative hour.
Incidence of opioid-Emergent Adverse Events [Safety and Tolerability]3 daysMeasuring the incidence rate of common side effects associated with morphine drugs
Opioid consumption in Morphine Milligram Equivalents after the first 48 hours post-surgery.48 hours post-surgeryEvaluation of the total consumption of morphine equivalents (Oxycodone Hydrochloride) after the first 48 hours postoperative hour.
Evaluation of patient satisfaction about medical care3 days (maximum)The patient's feelings and satisfaction with their care will be evaluated by completing the questionnaire The feeling and satisfaction is rated according to a scale of 5 categories as follows: None, Low, Medium, High and Very High
Incidence of regional anesthesia-Emergent Adverse Event [Safety and Tolerability]3 daysMeasuring the incidence rate of common side effects associated with regional anesthesia
Evaluation of preoperative anxiety and fear using Amsterdam Preoperative Anxiety and Information Scale on post-surgical painpré-anesthesic visit (day -1 or day 0)The patient's degree of pre-operative anxiety will be assessed using the Amsterdam Preoperative Anxiety and Information questionnaire in French Items are rated on a 5-point Likert scale ranging from 1 = not at all to 5 = extremely

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026